Hematology 2021 Leukemias

CME

Key Studies in Leukemias: Independent Conference Coverage of ASH 2021

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: April 06, 2022

Expiration: April 05, 2023

Activity

Progress
1
Course Completed

At the ASH 2021 annual meeting in Atlanta, Georgia, new clinical data were reported in the settings of acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and acute lymphoblastic leukemia (ALL). In this expert analysis module, B. Douglas Smith, MD, and Eunice S. Wang, MD, review and discuss the clinical implications of key findings for these diseases that were presented at the meeting.

Please note that the slide thumbnails embedded in this activity link to short PowerPoint slidesets, each focused on the specific study of interest. The slides for the studies covered in this activity may be downloaded by clicking on any of the thumbnails within the activity.

Clinical Care Options plans to measure the educational impact of this activity. Several questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before we begin this educational activity, please take a moment to answer the following questions.

If you are a practicing healthcare professional, how many patients with leukemia do you provide care for in a typical month?

When considering treatment selection for a patient with newly diagnosed poor-risk AML, patients with which of the following risk factors would most benefit from HMA plus venetoclax therapy vs azacitidine monotherapy according to results from a retrospective study by Pollyea and colleagues?

When discussing treatment options with your patient with newly diagnosed AML, which of the following results would you identify as shown with liposomal daunorubicin/cytarabine (CPX-351) compared with a hypomethylating agent (HMA) plus venetoclax in a real-world retrospective study?

When discussing asciminib treatment for your patients with Philadelphia chromosome (Ph)-positive CML, which adverse event (AE) would you tell them is most common with this drug based on clinical trials?